Emmaus Life Sciences Announces SFDA (Saudi Food & Drug Authority) Accepts Endari® Priority Review Request

TORRANCE, Calif., April 16, 2020 (GLOBE NEWSWIRE) — Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease? treatment, announced today that the SFDA (Saudi Food & Drug Authority) has accepted its request for priority review of Endari?, its prescription grade L-glutamine oral powder. Similar to the U.S. Food & Drug Administration (FDA), priority review by the SFDA in Saudi Arabia is a program designated to expedite the review process for drugs that are expected to have a particularly significant positive impact on the treatment of a disease.